Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N Engl J Med, vol.378, pp.439-448, 2018. ,
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy, Biology of Blood and Marrow Transplantation, vol.25, pp.76-85, 2019. ,
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, vol.129, pp.3322-3331, 2017. ,
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia, Nat Med, vol.24, pp.1504-1506, 2018. ,
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis, Journal of Immunotherapy, vol.40, pp.187-195, 2017. ,
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19, Leukemia, 2019. ,
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy, Cancer Discovery, vol.5, pp.1282-1295, 2015. ,
Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics, Genome Biol, vol.19, p.224, 2018. ,
Massively parallel digital transcriptional profiling of single cells, Nat Commun, vol.8, p.14049, 2017. ,
Integrating single-cell transcriptomic data across different conditions, technologies, and species, Nat. Biotechnol, vol.36, pp.411-420, 2018. ,
KLF6, a Candidate Tumor Suppressor Gene Mutated in Prostate Cancer, Science, vol.294, pp.2563-2566, 2001. ,
Krüppel-like factors in cancer, Nat Rev Cancer, vol.13, pp.701-713, 2013. ,
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia, N Engl J Med, vol.368, pp.1509-1518, 2013. ,
A covalent and cleavable antibody-DNA conjugation strategy for sensitive protein detection via immuno-PCR, Sci Rep, vol.6, p.22675, 2016. ,
Comprehensive Integration of Single-Cell Data, Cell, vol.177, 1888. ,
Massively parallel digital transcriptional profiling of single cells, Nat Commun, vol.8, p.14049, 2017. ,
Integrating single-cell transcriptomic data across different conditions, technologies, and species, Nat. Biotechnol, vol.36, pp.411-420, 2018. ,
SCENIC: single-cell regulatory network inference and clustering, Nat. Methods, vol.14, pp.1083-1086, 2017. ,
, où de nombreux paramètres influencent à la fois l'efficacité, la tolérance, l'accessibilité ou le prix du médicament. Cette nouvelle thérapie s'avère être une approche efficace pour traiter les patients atteints de LAL-B réfractaires à la thérapie conventionnelle. Cependant, environ 35% des patients rechutent et plus de la moitié de ces rechutes sont CD19-négatives. Des études antérieures ont examiné le mécanisme d'inhibition de l'expression du CD19, mais à ce jour, Les CAR-T cells ciblant l'antigène CD19 sont des médicaments d'un genre nouveau
, Nous avons ainsi abordé cette question et démontré que de rares clones de LAL-B
, ce qui implique que la rechute résulterait d'une sélection Darwinienne de rares sous-clones préexistants, et non du traitement par les cellules CAR-T en soi. Ainsi, l'avancée majeure de notre étude est que nous pouvons détecter RÉFÉRENCES BIBLIOGRAPHIQUES 1. Immunothérapie : mode d'action -Thérapies ciblées et immunothérapie spécifique | Institut National Du Cancer, CD19-négatifs étaient présents avant CAR-T cells
Development of immuno-oncology drugs -from CTLA4 to PD1 to the next generations, Nat. Rev. Drug Discov, vol.15, issue.4, pp.235-247, 2016. ,
Blinatumomab: A novel, bispecific, T-cell engaging antibody, Am. J. Health-Syst. Pharm. AJHP Off. J. Am. Soc. Health-Syst. Pharm, vol.73, issue.1, pp.6-13, 2016. ,
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes, Science, vol.233, issue.4770, pp.1318-1321, 1986. ,
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes, Science, vol.314, issue.5796, pp.126-129, 2006. ,
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, vol.114, issue.3, pp.535-546, 2009. ,
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy, J. Immunother. Hagerstown Md, vol.36, issue.2, pp.133-151, 1997. ,
Different affinity windows for virus and cancerspecific T-cell receptors: implications for therapeutic strategies, Eur. J. Immunol, vol.42, issue.12, pp.3174-3179, 2012. ,
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia, Sci. Transl. Med, vol.7, issue.303, pp.303-139, 2015. ,
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia, N. Engl. J. Med, vol.378, issue.5, pp.439-448, 2018. ,
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, vol.129, issue.25, pp.3322-3331, 2017. ,
Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis, Blood, vol.128, issue.22, pp.2801-2801, 2016. ,
Pour comprendre : l'activation lymphocytaire T, Bull. Cancer (Paris), vol.103, pp.127-131, 2016. ,
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy, JNCI J. Natl. Cancer Inst, vol.108, issue.7, 2016. ,
Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma, Cancer Sci, vol.108, issue.6, pp.1109-1118, 2017. ,
Engineering CAR-T cells, Biomark. Res, vol.5, issue.1, p.22, 2017. ,
Driving CAR T-cells forward, Nat. Rev. Clin. Oncol, vol.13, issue.6, pp.370-383, 2016. ,
Universal CARs, universal T cells, and universal CAR T cells, J. Hematol. Oncol.J Hematol Oncol, vol.11, issue.1, p.132, 2018. ,
CAR-T cells : indications actuelles en pédiatrie et perspectives de développement, Bull. Cancer (Paris), vol.105, pp.147-157, 2018. ,
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity, Proc. Natl. Acad. Sci, vol.86, issue.24, pp.10024-10028, 1989. ,
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors, Proc. Natl. Acad. Sci. U. S. A, vol.90, issue.2, pp.720-724, 1993. ,
Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment, Protein Cell, vol.8, issue.12, pp.896-925, 2017. ,
, concepts et principes des CAR-T cells, vol.105, pp.135-146, 2018.
Signals through T cell receptor-zeta chain alone are insufficient to prime resting T lymphocytes, J. Exp. Med, vol.181, issue.5, pp.1653-1659, 1995. ,
Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells, Blood, vol.96, issue.5, pp.1999-2001, 2000. ,
The pharmacology of second-generation chimeric antigen receptors, Nat. Rev. Drug Discov, vol.14, issue.7, pp.499-509, 2015. ,
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR? /CD28 receptor, Nat. Biotechnol, vol.20, issue.1, pp.70-75, 2002. ,
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia, Leukemia, vol.18, issue.4, pp.676-684, 2004. ,
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells, Cancer Cell, vol.28, issue.4, pp.415-428, 2015. ,
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling, Int. J. Cancer, vol.129, issue.12, pp.2935-2944, 2011. ,
,
,
TRUCKs: the fourth generation of CARs, Expert Opin. Biol. Ther, vol.15, issue.8, pp.1145-1154, 2015. ,
IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression, Cancer Res, vol.71, issue.17, pp.5697-5706, 2011. ,
, Immunothérapies spécifiques dans le traitement des cancers : rapport et une synthèse
Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells, Cancer Gene Ther, vol.22, issue.2, pp.79-84, 2015. ,
Therapeutic T cell engineering, Nature, vol.545, issue.7655, pp.423-431, 2017. ,
Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo, Leukemia, vol.30, issue.2, pp.492-500, 2016. ,
Design of retroviral vectors and helper cells for gene therapy, Pharmacol. Rev, vol.52, issue.4, pp.493-511, 2000. ,
Clinical use of lentiviral vectors, Leukemia, vol.32, issue.7, pp.1529-1541, 2018. ,
Safe engineering of CAR T cells for adoptive cell therapy of cancer using long term episomal gene transfer, EMBO Mol. Med, vol.8, issue.7, pp.702-711, 2016. ,
PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts, Mol. Ther, vol.26, issue.8, pp.1883-1895, 2018. ,
Redirecting Specificity of T-Cell Populations For CD19 Using the Sleeping Beauty System, Cancer Res, vol.68, issue.8, pp.2961-2971, 2008. ,
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers, Nat. Nanotechnol, vol.12, issue.8, pp.813-820, 2017. ,
Bioreactors get personal, OncoImmunology, vol.1, issue.8, pp.1435-1437, 2012. ,
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE), Haematologica, vol.105, issue.2, pp.297-316, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-02485853
Challenges and opportunities of allogeneic donor-derived CAR T cells, Curr. Opin. Hematol, vol.22, issue.6, pp.509-515, 2015. ,
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells, Sci. Transl. Med, vol.9, issue.374, p.2013, 2017. ,
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia, Drug Des. Devel. Ther, vol.12, pp.3885-3898, 2018. ,
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy, Nat. Med, vol.24, issue.1, pp.20-28, 2018. ,
B-cell targeting in rheumatoid arthritis and other autoimmune diseases, Nat. Rev. Immunol, vol.6, issue.5, pp.394-403, 2006. ,
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications, Blood, vol.117, pp.5019-5032, 2011. ,
Acute lymphoblastic leukemia: a comprehensive review and 2017 update, Blood Cancer J, vol.7, issue.6, pp.577-577, 2017. ,
Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, J. Natl. Compr. Cancer Netw. JNCCN, vol.18, issue.1, pp.81-112, 2020. ,
, Orphanet: Leucémie lymphoblastique aiguë
Chapitre 4: Item 312 -UE 9 Leucémies aiguës. 3ème édition, 2018. ,
Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL), Leukemia, vol.9, issue.10, pp.1783-1786, 1995. ,
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, vol.127, issue.20, pp.2391-2405, 2016. ,
Acute Lymphoblastic Leukemia in Children, N. Engl. J. Med, vol.373, issue.16, pp.1541-1552, 2015. ,
Treatment of Pediatric Acute Lymphoblastic Leukemia, Pediatr. Clin. North Am, vol.62, issue.1, pp.61-73, 2015. ,
, NCCN Clinical Practice Guidelines in Oncology. Acute lymphoblastic Leukemia, 2018.
Childhood acute lymphoblastic leukaemia and relapse, Br. J. Haematol, vol.131, issue.5, pp.579-587, 2005. ,
,
Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy, Biol. Blood Marrow Transplant, vol.25, issue.3, pp.76-85, 2019. ,
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, The Lancet, vol.385, issue.9967, pp.517-528, 2015. ,
Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation, Blood, vol.128, issue.22, pp.218-218, 2016. ,
Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia, Blood, vol.132, pp.895-895, 2018. ,
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL, Blood, vol.134, issue.26, pp.2361-2368, 2019. ,
, Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients -Full Text View -ClinicalTrials.gov
, Tisagenlecleucel Versus Blinatumomab or Inotuzumab for Adult Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia: A Randomized Open Label, Multicenter, Phase III Trial. clinicaltrials.gov, Novartis Pharmaceuticals, 2020.
Toxicities of chimeric antigen receptor T cells: recognition and management, Blood, vol.127, issue.26, pp.3321-3330, 2016. ,
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia, N. Engl. J. Med, vol.371, issue.16, pp.1507-1517, 2014. ,
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction, Cancer Discov, vol.10, issue.4, pp.552-567, 2020. ,
Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies, Front. Immunol, vol.10, p.2664, 2019. ,
Humanized CD19-specific chimeric antigen-receptor Tcells in 2 adults with newly diagnosed B-cell acute lymphoblastic leukemia, Leukemia, vol.33, issue.11, pp.2751-2753, 2019. ,
Efficacy of Humanized CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells in Children and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia, Blood, vol.128, issue.22, pp.217-217, 2016. ,
Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy, Blood, vol.132, pp.4022-4022, 2018. ,
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia, Nat. Med, vol.24, issue.10, pp.1504-1506, 2018. ,
Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy, Cancer Discov, vol.5, issue.12, pp.1282-1295, 2015. ,
Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling, Blood, vol.118, issue.15, pp.112-117, 2011. ,
Aberrant RNA Splicing in Cancer and Drug Resistance, Cancers, vol.10, issue.11, p.458, 2018. ,
,
, Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis, J. Immunother, vol.40, issue.5, pp.187-195, 2017.
Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19, Leukemia, 2019. ,
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia, N. Engl. J. Med, vol.368, issue.16, pp.1509-1518, 2013. ,
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, vol.127, issue.20, pp.2406-2410, 2016. ,
Current concepts in the diagnosis and management of cytokine release syndrome, Blood, vol.124, issue.2, pp.188-195, 2014. ,
Interleukin 6 induces myeloid differentiation of a human biphenotypic leukemic cell line, Leuk. Res, vol.16, issue.8, pp.751-760, 1992. ,
IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development, Cancer Cell, vol.20, issue.5, pp.661-673, 2011. ,
Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy. Transl, Cancer Res, vol.5, issue.S2, pp.221-225, 2016. ,
Phenotype switch in acute lymphoblastic leukaemia associated with 3 years of persistent CAR T cell directed-CD19 selective pressure, Br. J. Haematol, vol.186, issue.2, pp.333-336, 2019. ,
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape, Nature, vol.568, issue.7750, pp.112-116, 2019. ,
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell, Nat. Med, vol.24, issue.10, pp.1499-1503, 2018. ,
Simultaneous epitope and transcriptome measurement in single cells, Nat. Methods, vol.14, issue.9, pp.865-868, 2017. ,
Integrating single-cell transcriptomic data across different conditions, technologies, and species, Nat. Biotechnol, vol.36, issue.5, pp.411-420, 2018. ,
, Index -Single Cell Gene Expression -Official 10x Genomics Support
Immuno-Detection by sequencing (IDseq) enables large-scale high-dimensional phenotyping in cells, p.158139, 2017. ,
, CITE-seq Hyper Antibody-Oligo Conjugation
, Index -Single Cell Immune Profiling -Official 10x Genomics Support
,
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia, Leukemia, vol.33, issue.12, pp.2854-2866, 2019. ,
CAR-T cells et leucémies aiguës lymphoblastiques : avancées et questionnements, Bull. Cancer (Paris), vol.107, issue.2, pp.234-243, 2020. ,
Phase 1 study of CD19/CD22 bispecific chimeric antigen receptor (CAR) therapy in children and young adults with B cell acute lymphoblastic leuke-mia (ALL), Blood, vol.132, p.898, 2018. ,
Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies, J. Clin. Invest, vol.126, issue.10, pp.3814-3826, 2016. ,
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits, Cell, vol.164, issue.4, pp.770-779, 2016. ,
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22, Mol. Ther. Oncolytics, vol.11, pp.127-137, 2018. ,
A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy, Mol. Ther. -Nucleic Acids, vol.2, p.105, 2013. ,
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia, J. Autoimmun, vol.85, pp.141-152, 2017. ,
, CAR-T cells : des médicaments prometteurs, que la HAS réévaluera pour en confirmer le potentiel. Haute Autorité de santé